Aushon BioSystems, Inc., a leading provider of advanced microarray instrumentation and laboratory services for biomarker discovery, development and analysis announced today that the Institute for Molecular Medicine Finland (FIMM) will launch a cell microarray screening research program utilizing the Aushon 2470 Arrayer technology. This program consists of miniaturized RNA interference screens, and will also include compound/drug arrays in the future. FIMM is an international research institute with state-of-the-art technologies, and through its Technology Centre, provides academic core services at the University of Helsinki, FIMM partner institutions, and national and international collaborators, including the Biocenter Finland network.
“One of our primary applications will be siRNA cell microarray screening. We believe that our technology, developed together with the VTT Technical Research Centre, is ground-breaking and will provide an exciting opportunity for miniaturized, genome-scale cell biology and cellular pharmacology,” said Professor Olli Kallioniemi, Director, FIMM. “We intend to make use of the Aushon 2470 Arrayer’s throughput and capabilities in this particular application. As we are using an unusual siRNA, lipid, matrix combination as a printing mixture, the ability of the 2470’s solid pin deposition technology to handle complex samples is promising.”
The Aushon 2470 Arrayer has been installed in leading institutions throughout North America, Europe and Asia to provide rapid, accurate, high-density microarray printing for both genomic and proteomic applications. It is able to print virtually any sample – including cell lysates and blood – onto substrates with unique shapes and chemistries, as well as the most delicate of substrates such as nitrocellulose and silicon chips. Engineered with walk-away automation, the unique solid pin architecture and proprietary pin design make the 2470 the most flexible and reliable microarray printing platform available.
Date: March 25, 2010
Source: Aushon BioSystems, Inc.